BMRNBioMarin Pharmaceutical Inc.

$12B

FY 2013 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$548M+9.5% YoY

Gross Profit

$460M83.9% margin

Operating Income

-$156M-28.4% margin

Net Income

-$176M-32.2% margin

EPS (Diluted)

$-1.28

Cash Flow

Operating Cash Flow

-$60M

Free Cash Flow

-$125M

Stock-Based Comp.

$66M

Balance Sheet

Total Assets

$2.2B

Total Liabilities

$903M

Stockholders' Equity

$1.3B

Cash & Equivalents

$569M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$548M	$501M	+9.5%
Gross Profit	$460M	$409M	+12.5%
Operating Income	-$156M	-$110M	-41.5%
Net Income	-$176M	-$114M	-54.2%

BMRN FY 2013 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena